AT WHAT LEVEL OF COLLECTIVE EQUIPOISE DOES A CLINICAL-TRIAL BECOME ETHICAL

被引:88
|
作者
JOHNSON, N
LILFORD, RJ
BRAZIER, W
机构
关键词
CLINICAL TRIALS;
D O I
10.1136/jme.17.1.30
中图分类号
B82 [伦理学(道德学)];
学科分类号
摘要
It has often been argued that if a clinician cannot decide which of two treatments to offer, a trial may be ethical, but it is unethical if she/he has a preference. Since individual clinicians usually have a preference, most trials could be judged unethical according to this line of argument. A recent important article in the New England Journal of Medicine argued that individual preferences are not as important as the collective uncertainty of informed clinicians. If clinicians are equally divided, there is a state of collective equipoise and a trial is ethical. However, clinicians will seldom be exactly equally divided. We conducted an ethometric study to find out how much collective equipoise can be disturbed before the potential subjects in a trial think that it is unethical. Half of our subjects perceived a trial as unethical when equipoise was disturbed beyond 70:30. In other words, when 70 per cent of experts favour one treatment, 50 per cent of subjects would prefer that treatment to be administered rather than subjected to critical assessment. When equipoise is disturbed beyond 80:20, less than 3 per cent of subjects would consider human trials morally justifiable.
引用
收藏
页码:30 / 34
页数:5
相关论文
共 50 条
  • [11] TOWARDS A MORE ETHICAL CLINICAL-TRIAL DESIGN - THE RANDOMIZED PLACEBO PHASE DESIGN (RPPD)
    FELDMAN, BM
    SZALAI, JP
    ARTHRITIS AND RHEUMATISM, 1995, 38 (09): : 146 - 146
  • [12] AT WHAT LEVEL DOES PSYCHIATRIC CLINICAL SPECIALIST PRACTICE
    HENRION, RP
    JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES, 1974, 12 (03) : 14 - 18
  • [13] ETHICAL CONSIDERATIONS IN THE DESIGN OF A RANDOMIZED CLINICAL-TRIAL OF NUTRITIONAL THERAPY FOR CHRONIC RENAL-DISEASE
    SANDBERG, AM
    WILLIAMS, GW
    LEVEY, AS
    CONTROLLED CLINICAL TRIALS, 1988, 9 (03): : 254 - 254
  • [14] EARLY INDOMETHACIN (IND) DOES NOT PREVENT BRONCHOPULMONARY DYSPLASIA (BPD) IN A RANDOMIZED CLINICAL-TRIAL
    VINCER, MJ
    ALLEN, AC
    STINSON, DA
    EVANS, JR
    NWAESEI, CG
    REES, E
    FRASER, A
    CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, 1985, 8 (03): : A175 - A175
  • [15] EARLY INDOMETHACIN (IND) DOES NOT PREVENT BRONCHOPULMONARY DYSPLASIA (BPD) IN A RANDOMIZED CLINICAL-TRIAL
    VINCER, MJ
    ALLEN, AC
    STINSON, DA
    EVANS, JR
    NWAESEI, CG
    REES, E
    FRASER, A
    PEDIATRIC RESEARCH, 1985, 19 (04) : A369 - A369
  • [16] DOES TAMOXIFEN INFLUENCE SURVIVAL IN PANCREATIC-CANCER - A RANDOMIZED CONTROLLED CLINICAL-TRIAL
    TAYLOR, OM
    MCMAHON, MJ
    BENSON, EA
    GUT, 1989, 30 (10) : A1457 - A1457
  • [17] WHAT MAKES A CLINICAL-TRIAL REPORT HELPFUL - A PRELIMINARY-ANALYSIS OF RHEUMATOLOGISTS JUDGEMENTS
    DESAINTONGE, DMC
    HATTERSLEY, LA
    KIRWAN, JR
    BRITISH JOURNAL OF RHEUMATOLOGY, 1983, 22 (03): : 59 - 66
  • [18] WHY DOES MIGRAINE IMPROVE DURING A CLINICAL-TRIAL - FURTHER RESULTS FROM A TRIAL OF CERVICAL MANIPULATION FOR MIGRAINE
    PARKER, GB
    PRYOR, DS
    TUPLING, H
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1980, 10 (02): : 192 - 198
  • [19] DOES MASS CLOSURE OF MIDLINE LAPAROTOMIES STAND THE TEST OF TIME - A RANDOM CONTROL CLINICAL-TRIAL
    AUSOBSKY, JR
    EVANS, M
    POLLOCK, AV
    ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND, 1985, 67 (03) : 159 - 161
  • [20] What difference does it make to be treated in a clinical trial? A pilot study
    Weijer, C
    Freedman, B
    Fuks, A
    Robbins, J
    Shapiro, S
    Skrutkowska, M
    CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, 1996, 19 (03): : 179 - 183